Investor Centre

Pharmaxis is pleased to advise that it has received notification from the European Commission that processing of the Marketing Authorisation application for Bronchitol to treat cystic fibrosis is nearing completion.

The European Commission procedure is expected to conclude next month and Pharmaxis is proceeding with plans for a commercial launch of Bronchitol later in the second quarter in anticipation of a successful outcome. The first commercial launch will be in Germany and the UK, and will be followed by other countries as pricing and reimbursement negotiations are concluded.